CN103596982B - 治疗性抗体 - Google Patents

治疗性抗体 Download PDF

Info

Publication number
CN103596982B
CN103596982B CN201280028064.1A CN201280028064A CN103596982B CN 103596982 B CN103596982 B CN 103596982B CN 201280028064 A CN201280028064 A CN 201280028064A CN 103596982 B CN103596982 B CN 103596982B
Authority
CN
China
Prior art keywords
antibody
seq
sequence
variable region
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280028064.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103596982A (zh
Inventor
S.扎恩
L.H.泽尤特恩
A.J.汉森
K.克杰加亚尔德
S.伦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN103596982A publication Critical patent/CN103596982A/zh
Application granted granted Critical
Publication of CN103596982B publication Critical patent/CN103596982B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
CN201280028064.1A 2011-06-06 2012-06-04 治疗性抗体 Active CN103596982B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11168787.7 2011-06-06
EP11168787 2011-06-06
US201161505137P 2011-07-07 2011-07-07
US61/505137 2011-07-07
EP12159172.1 2012-03-13
EP12159172 2012-03-13
PCT/EP2012/060524 WO2012168199A1 (en) 2011-06-06 2012-06-04 Therapeutic antibodies

Publications (2)

Publication Number Publication Date
CN103596982A CN103596982A (zh) 2014-02-19
CN103596982B true CN103596982B (zh) 2016-11-02

Family

ID=47295509

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280028064.1A Active CN103596982B (zh) 2011-06-06 2012-06-04 治疗性抗体

Country Status (16)

Country Link
US (7) US8613926B2 (enExample)
EP (3) EP3424953B1 (enExample)
JP (2) JP6141834B2 (enExample)
KR (1) KR101978757B1 (enExample)
CN (1) CN103596982B (enExample)
AU (1) AU2012266487B2 (enExample)
BR (1) BR112013031198B1 (enExample)
CA (1) CA2838497C (enExample)
DK (3) DK3424953T3 (enExample)
ES (2) ES2693647T3 (enExample)
IL (1) IL229254A (enExample)
PL (2) PL2718322T3 (enExample)
PT (1) PT3424953T (enExample)
RU (1) RU2616881C2 (enExample)
TW (1) TWI564305B (enExample)
WO (1) WO2012168199A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2616881C2 (ru) 2011-06-06 2017-04-18 Ново Нордиск А/С Терапевтические антитела
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
EP3626748A1 (en) * 2014-01-13 2020-03-25 Stephen J. Forman Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
US20170107294A1 (en) * 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
SG11201700496WA (en) 2014-07-22 2017-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
US20170328898A1 (en) * 2014-10-31 2017-11-16 Cell Trend GmbH Diagnosis of an autoimmune disease using detection of antibodies directed against c5a-receptor
BR112018009129A2 (pt) * 2015-11-04 2019-02-26 J. PRICEMAN Saul receptores de antígeno quimérico que visam her2
JP2019509014A (ja) * 2015-11-23 2019-04-04 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｃｄ３９血管アイソフォームターゲティング剤
HRP20231578T1 (hr) 2015-11-25 2024-03-15 Visterra, Inc. Molekule protutijela na april i njihove uporabe
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
AR107505A1 (es) 2016-01-22 2018-05-09 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulación xi
KR102218714B1 (ko) 2016-06-14 2021-02-24 머크 샤프 앤드 돔 코포레이션 항응고 인자 xi 항체
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
PT3500299T (pt) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
IL269150B2 (en) 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
IL270596B1 (en) * 2017-05-25 2025-09-01 Bristol Myers Squibb Co Antibodies comprising modified heavy constant region for use in treating cancer
TW202515616A (zh) 2017-06-26 2025-04-16 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
EP3668898B1 (en) * 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
WO2019092148A1 (en) * 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
BR112020024412A8 (pt) 2018-06-18 2023-03-21 Innate Pharma Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação
KR20210060477A (ko) 2018-09-17 2021-05-26 압큐로, 인크. 항-klrg1 항체
JP2022513708A (ja) * 2018-12-05 2022-02-09 モルフォシス・アーゲー 多重特異性抗原結合分子
JP7617012B2 (ja) 2019-03-14 2025-01-17 モルフォシス・アーゲー Ｃ５ａＲを標的とする抗体
BR112022010757A2 (pt) * 2019-12-03 2022-08-16 Shanghai Jiao Tong Univ School Of Medicine Região de anticorpo fc com afinidade de ligação aumentada para fc-gama-riib.
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
EP4196501A1 (en) 2020-08-12 2023-06-21 Innate Pharma Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab
TW202233677A (zh) 2020-11-02 2022-09-01 新加坡商蜂鳥生物科技私人有限公司 Bcma/taci抗原結合分子
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
JP2024512386A (ja) 2021-03-12 2024-03-19 ジェンマブ エー／エス 非活性化抗体バリアント
WO2023041745A1 (en) 2021-09-16 2023-03-23 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
WO2023046979A1 (en) 2021-09-27 2023-03-30 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
JP7503215B2 (ja) 2021-10-08 2024-06-19 ジェンマブ エー／エス Ｃｄ３０及びｃｄ３に結合する抗体
CN118382456A (zh) * 2021-12-16 2024-07-23 上海宝济药业股份有限公司 抗免疫球蛋白降解酶酶切的Fc变体
TW202409280A (zh) 2022-07-08 2024-03-01 新加坡科技研究局 Cnx抗原結合分子
EP4577578A1 (en) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
WO2024062073A1 (en) 2022-09-22 2024-03-28 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
WO2024147097A1 (en) 2023-01-03 2024-07-11 Hummingbird Bioscience Pte. Ltd. Her3-binding antibody-drug conjugate
EP4646225A1 (en) 2023-01-06 2025-11-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
WO2024146955A1 (en) 2023-01-06 2024-07-11 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
WO2025125495A1 (en) 2023-12-13 2025-06-19 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
WO2025133322A1 (en) 2023-12-22 2025-06-26 Agency For Science, Technology And Research Cnx antigen-binding molecules
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062278A1 (en) * 2002-01-25 2003-07-31 G2 Therapies Ltd MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
CN101506237A (zh) * 2006-08-22 2009-08-12 G2炎症私人有限公司 具有改进性能的抗-C5aR抗体

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JPH02262599A (ja) 1989-01-03 1990-10-25 Merck & Co Inc ヒト多形核白血球からの精製Ｃ５ａレセプター
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1994007921A1 (en) 1992-09-25 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5861272A (en) 1995-06-02 1999-01-19 Human Genome Sciences, Inc. C5A receptor
US20010036650A1 (en) 1994-08-16 2001-11-01 Human Genome Sciences, Inc. C5a receptor
JPH08109200A (ja) 1994-08-19 1996-04-30 Takeda Chem Ind Ltd 抗Ｃ５ａレセプター抗体、その製造法および用途
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP0832231A2 (en) 1995-06-05 1998-04-01 Incyte Pharmaceuticals, Inc. A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
JP2001511645A (ja) 1997-01-31 2001-08-14 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトＣ５ａ様受容体
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
AU2002231194A1 (en) 2000-11-07 2002-05-21 Genetics Institute, Llc G protein-coupled receptor protein and nucleic acid molecules and uses therefor
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
WO2002059263A2 (en) 2000-12-19 2002-08-01 Sunol Molecular Corporation Transgenic animals comprising a humanized immune system
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TWI334439B (en) * 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
EP1438325B1 (en) 2001-09-27 2009-12-30 Merck & Co., Inc. Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
JP2006513702A (ja) 2002-09-09 2006-04-27 ヌラ インコーポレーティッド Ｇタンパク質共役受容体およびその使用
AU2002952086A0 (en) 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
ATE412903T1 (de) 2003-03-17 2008-11-15 Bayer Healthcare Ag Diagnostik- und therapie- verfahren von mit c5a rezeptor verbundenen krankheiten
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
AU2004304665B2 (en) 2003-12-24 2009-03-12 Novo Nordisk A/S Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR
EP1586583A3 (en) 2004-04-16 2005-11-16 Alligator Bioscience AB (publ) Compounds that block C5a complement receptor and their use in therapy
EA015584B1 (ru) * 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
WO2007055374A1 (ja) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation 骨粗鬆症治療剤
JP2010501165A (ja) 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
EP2203180B1 (en) * 2007-10-22 2012-11-21 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
KR20100117120A (ko) 2008-02-20 2010-11-02 지투 인플레메이션 피티와이 엘티디 인간화된 항-Ｃ5ａＲ 항체
WO2009149081A1 (en) 2008-06-02 2009-12-10 Novelmed Therapeutics, Inc. Method for treating inflammatory conditions
US20090324585A1 (en) 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
WO2010000864A1 (en) 2008-07-04 2010-01-07 Novo Nordisk A/S Method for producing monoclonal antibodies
ES2577548T3 (es) * 2008-12-22 2016-07-15 Chemocentryx, Inc. Antagonistas de C5aR
WO2011100477A2 (en) 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
CA2800188A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
CN103080135B (zh) * 2010-06-30 2017-06-13 诺沃—诺迪斯克有限公司 能够特异性结合组织因子途径抑制剂的抗体
US20130183280A1 (en) * 2010-07-15 2013-07-18 Novo Nordisk A/S Stabilized factor viii variants
WO2012088247A2 (en) * 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
RU2616881C2 (ru) * 2011-06-06 2017-04-18 Ново Нордиск А/С Терапевтические антитела
DK2994488T3 (da) 2013-05-08 2022-10-03 Novo Nordisk As Anvendelse af c5ar-antagonister

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062278A1 (en) * 2002-01-25 2003-07-31 G2 Therapies Ltd MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
CN101506237A (zh) * 2006-08-22 2009-08-12 G2炎症私人有限公司 具有改进性能的抗-C5aR抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Optimization of Fc-mediated effector functions of monoclonal antibodies;William R Strohl;《Current Opinion in Biotechnology》;20091104;第20卷(第6期);第687页右栏倒数第1段和第688页表2 *

Also Published As

Publication number Publication date
PT3424953T (pt) 2020-11-03
EP3798230B1 (en) 2022-08-03
JP6141834B2 (ja) 2017-06-07
WO2012168199A1 (en) 2012-12-13
US20210238300A1 (en) 2021-08-05
KR20140036261A (ko) 2014-03-25
EP3798230A1 (en) 2021-03-31
EP3424953B1 (en) 2020-08-05
ES2693647T3 (es) 2018-12-13
US20200017599A1 (en) 2020-01-16
BR112013031198A2 (pt) 2016-11-29
DK2718322T3 (en) 2018-12-03
KR101978757B1 (ko) 2019-05-15
RU2616881C2 (ru) 2017-04-18
CN103596982A (zh) 2014-02-19
US8846045B2 (en) 2014-09-30
JP2017081941A (ja) 2017-05-18
BR112013031198B1 (pt) 2020-10-20
EP3424953A1 (en) 2019-01-09
TWI564305B (zh) 2017-01-01
ES2929575T3 (es) 2022-11-30
JP2014523408A (ja) 2014-09-11
PL3424953T3 (pl) 2021-01-25
US20130004514A1 (en) 2013-01-03
IL229254A0 (en) 2014-01-30
US10882916B2 (en) 2021-01-05
EP2718322A1 (en) 2014-04-16
JP6416177B2 (ja) 2018-10-31
DK3798230T3 (en) 2022-10-31
CA2838497A1 (en) 2012-12-13
US20150044231A1 (en) 2015-02-12
TW201311724A (zh) 2013-03-16
RU2013155029A (ru) 2015-07-20
BR112013031198A8 (pt) 2018-01-16
US10323097B2 (en) 2019-06-18
US20170073421A1 (en) 2017-03-16
CA2838497C (en) 2023-02-28
US20240218076A1 (en) 2024-07-04
IL229254A (en) 2017-09-28
AU2012266487A1 (en) 2013-11-21
DK3424953T3 (en) 2020-11-02
US20130295116A1 (en) 2013-11-07
US8613926B2 (en) 2013-12-24
PL2718322T3 (pl) 2019-07-31
AU2012266487B2 (en) 2016-12-08
EP2718322B1 (en) 2018-08-08

Similar Documents

Publication Publication Date Title
CN103596982B (zh) 治疗性抗体
CA3154540A1 (en) Caninized antibodies
KR20220160542A (ko) C5ar1에 대한 항체 분자 및 이의 용도
AU2013269652A1 (en) TLR3 binding agents
WO2019086878A1 (en) Antibodies and methods of use
CN116670286A (zh) 用于免疫相关疾病的人抗tigit单克隆抗体
ES2831303T3 (es) Anticuerpos terapéuticos
CA3239307A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha 1
MX2013013911A (es) Anticuerpos terapeuticos.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant